Trident Lifeline Ltd
Incorporated in 2014, Trident Lifeline Ltd manufactures and sells pharmaceuticals
products[1]
- Market Cap ₹ 351 Cr.
- Current Price ₹ 300
- High / Low ₹ 325 / 222
- Stock P/E 23.0
- Book Value ₹ 69.8
- Dividend Yield 0.00 %
- ROCE 18.1 %
- ROE 20.0 %
- Face Value ₹ 10.0
Pros
- Company's working capital requirements have reduced from 208 days to 144 days
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding has decreased over last 3 years: -6.31%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|
| 22 | 32 | 45 | 87 | 103 | |
| 19 | 25 | 36 | 72 | 82 | |
| Operating Profit | 3 | 6 | 8 | 15 | 21 |
| OPM % | 12% | 20% | 18% | 17% | 21% |
| 1 | 1 | 2 | 8 | 7 | |
| Interest | 0 | 0 | 1 | 4 | 4 |
| Depreciation | 0 | 0 | 1 | 5 | 6 |
| Profit before tax | 3 | 7 | 9 | 14 | 18 |
| Tax % | -32% | 8% | 32% | 23% | |
| 4 | 6 | 6 | 10 | 14 | |
| EPS in Rs | 4.94 | 5.24 | 5.51 | 10.22 | 13.22 |
| Dividend Payout % | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 59% |
| TTM: | 86% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 44% |
| TTM: | 86% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 34% |
| 1 Year: | 7% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 18% |
| Last Year: | 20% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 8 | 12 | 12 | 12 | 12 |
| Reserves | -3 | 34 | 41 | 53 | 69 |
| 2 | 8 | 18 | 54 | 59 | |
| 7 | 9 | 16 | 37 | 47 | |
| Total Liabilities | 14 | 63 | 87 | 156 | 187 |
| 1 | 3 | 21 | 44 | 46 | |
| CWIP | 0 | 5 | 4 | 2 | 2 |
| Investments | 0 | 3 | 4 | 11 | 9 |
| 12 | 51 | 58 | 99 | 130 | |
| Total Assets | 14 | 63 | 87 | 156 | 187 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| -0 | -19 | 2 | -10 | |
| -0 | -10 | -20 | -14 | |
| 1 | 42 | 11 | 20 | |
| Net Cash Flow | 0 | 14 | -7 | -4 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Debtor Days | 83 | 139 | 110 | 116 |
| Inventory Days | 95 | 129 | 156 | 226 |
| Days Payable | 134 | 87 | 94 | 119 |
| Cash Conversion Cycle | 44 | 182 | 173 | 224 |
| Working Capital Days | 49 | 275 | 205 | 144 |
| ROCE % | 23% | 15% | 18% |
Documents
Announcements
-
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
10 Dec - Acquisition of 49,800 equity shares via warrant conversion on December 5, 2025; promoter stake rose to 6.33%
-
Announcement under Regulation 30 (LODR)-Allotment
5 Dec - Allotted 55,800 shares on Dec 5, 2025; Rs11,132,100 received; warrants converted at Rs266 each.
-
Board Meeting Outcome for Outcome Of Board Meeting Held On Today I.E. On December 05, 2025, In Terms Of Second Proviso To Regulation 30(6) Of SEBI (LODR) Regulations, 2015
5 Dec - On Dec 5, 2025, 55,800 shares allotted on warrant conversion; Rs.11,132,100 received; paid-up capital Rs.11,69,78,000.
-
Announcement under Regulation 30 (LODR)-Resignation of Director
21 Nov - 49,800 warrants converted to 49,800 shares; Rs9,935,100 received; non-exec director resigned effective 21-Nov-2025.
-
Announcement under Regulation 30 (LODR)-Allotment
21 Nov - Allotted 49,800 shares on Nov 21, 2025 at Rs.266; Rs9,935,100 received. Non-exec director Maniya H. Desai resigned.
Annual reports
Concalls
-
Nov 2025TranscriptAI SummaryPPT
-
Jul 2025TranscriptAI SummaryPPT
-
Oct 2024TranscriptAI SummaryPPT
-
Jul 2024TranscriptAI SummaryPPT
-
May 2024TranscriptAI SummaryPPT
-
Nov 2023TranscriptAI SummaryPPT
-
Jul 2023TranscriptAI SummaryPPT
-
May 2023TranscriptAI SummaryPPT
-
Jan 2023TranscriptAI SummaryPPT
Business Overview:[1]
TFL is a pharmaceutical Company with business operations spanning formulations under its own brands, loan licence model and contract manufacturing model.
a) Pharmaceutical formulations export:
Company has a presence in 40 countries, including African, Latin America, and East
Asian countries, with ~945 registered export market products, and ~2016 export market products are under registration
b) Contract manufacturing:
Company follows an Asset-light third-party contract manufacturing model thus entailing limited direct investment in manufacturing capacities